Clinical, family, and cost outcomes of preterm births: An overview of the problem and prevention opportunities

Journal of Clinical Outcomes Management

Volumn 14, Issue 10, 2007, Pages 547-553

  Armstrong, Joanne ^a,b,d   Meis, Paul J ^c  

^a AETNA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE CAPROATE;

CAUSE OF DEATH; CHILD DEATH; CHRONIC DISEASE; FAMILY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MORBIDITY; MORTALITY; NERVE CELL DIFFERENTIATION; OUTCOME ASSESSMENT; PREMATURE LABOR; REVIEW; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; UNITED STATES;

EID: 35748966990     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Martin JA, Hamilton BE, Sutton PD, et al. Births: Final data for 2004. National vital statistics reports; vol 55 no 1. Hyattsville (MD): National Center for Health Statistics; 2006. Available at www.cdc.gov/nchs/data/nvsr/ nvsr55/nvsr55_01.pdf. Accessed 6 Sep 2007.
2. Paneth NS. The problem of low birth weight. Future Child 1995;5:19-34.
3. Callaghan WM, MacDorman MF, Rasmussen SA, et al. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 2006;118:1566-73.
4. March of Dimes Perinatal Data Center. Peristats. Available at http://search.marchofdimes.com/cgi-bin/MsmGo.exe?grab_id=0&page_id= 4&query=peristats&hiword=peristats%20. Accessed 6 Sep 2007.
5. Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000;106:659-71.
6. Marlow N, Wolke D, Bracewell MA, et al. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9-19.
7. Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outomes of near-term infants. Pediatrics 2006;114:372-6.
8. Hack M Breslau N, Aram D, et al. The effect of very low birth weight and social risk on neurocognitive abilities at school age. J Dev Behav Pediatr 1992;13:412-20.
9. Hack M, Flannery DJ, Schluchter M, et al. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002;346:149-57.
10. Taylor HG, Minich NM, Klein N, Hack M. Longitudinal outcomes of very low birth weight: neuropsycological findings. J Int Neuropsychol Soc 2004;10:149-63.
11. Singer LT, Salvator A, Guo S, et al. Maternal psychological distress and parenting stress after the birth of a very low-birth weight infant. JAMA 1999;281:799-805.
12. Taylor HG, Klein N, Minich NM, Hack M. Long term family outcomes for children with very low birth weights. Arch Pediatr Adolesc Med 2001;155:155-61.
13. Saigal S, Burrows E, Stoskopf BL, et al. Impact of extreme prematurity on families of adolescent children. J Pediatr 2000;137:701-6.
14. Behrman RE, Butler AS, editors. Preterm birth: causes, consequences, and prevention. Washington (DC): National Academies Press; 2006.
15. Lewit EM, Baker LS, Corman H, Shiono PH. The direct cost of low birth weight. Future Child 1995;5:35-55.
16. Phibbs CS, Schmitt SK. Estimates of the cost and length of stay for changes that can be attributed to one-week increases in gestational age for premature infants. Early Hum Dev 2006;82:85-95.
17. Bailit JL, Votruba ME. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:219.e1-7.
18. Meis PJ, Michielutte R, Peters TJ, et al. Factors associated with preterm birth in Cardiff, Wales. II. Indicated and spontaneous preterm birth. Am J Obstet Gynecol 1995;173:597-602.
19. Shiono PH, Klebanoff MA. A review of risk scoring for preterm birth. Clin Perinatol 1993;20:107-25.
20. Mercer BM, Goldenberg RL, Das A, et al. The preterm prediction study: a clinical risk assessment system. Am J Obstet Gynecol 1996;174:1885-95.
21. Bakketeig LS, Hoffman HJ. Epidemiology of preterm birth: results from a longitudinal study of births in Norway. In: Elder MG, Hendricks CH, editors. Obstetrics and gynecology. Boston: Butterworths; 1981:17-46.
22. Adams MM, Elam-Evans LD, Wilson HG, Gilbertz DA. Rates of and factors associated with recurrence of preterm delivery. JAMA 2000;283:1591-6.
23. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999;94(5 Pt 2):869-77.
24. Harger JH. Cerclage and cervical insufficiency: an evidence-based analysis [published erratum appears in Obstet Gynecol 2003;101:205]. Obstet Gynecol 2002;100:1313-27.
25. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000;342:534-40.
26. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2001;345:487-93.
27. Creasy RK. Preterm birth prevention: where are we? Am J Obstet Gynecol 1993;168:1223-30.
28. Papiernik E. Double blind study of an agent to prevent preterm delivery among women at increased risk. Schering ed. Serie 4;1970:65-8.
29. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149-54.
30. Meis PJ, Connors N. Progesterone treatment to prevent preterm birth. Clin Obstet Gynecol 2004;47:784-95.
31. Meis PJ, Aleman A. Progesterone treatment to prevent preterm birth. Drugs 2004;64:2463-74.
32. Meis PJ. 17 hydroxyprogesterone for the prevention of preterm delivery. Society for Maternal-Fetal Medicine. Obstet Gynecol 2005;105(5 Pt 1):1128-35.
33. Petrini JR, Callaghan WM, Klebanoff M, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267-72.
34. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: A meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273-9.
35. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. American College of Obstetricians and Gynecologists. Obstet Gynecol 2003;102(5 Pt 1):1115-6.
36. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24.
37. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network [published erratum appears in N Engl J Med 2003;349:1299]. N Engl J Med 2003;348:2379-85.
38. Gonzalez-Quintero VH, Istwan NB, Rhea DJ, et al. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 2007;20:249-52.
39. Caritis S, Rouse D. A randomized trial of 17-hydroxy-progesterone caproate (17-OHPC) for the prevention of preterm birth in twins. Am J Obstet Gynecol 2006;195:S2.
40. Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980;56:692-5.
41. Reuters. Columbia Labs shares crash as gel trial fails. Available at www.reuters.com/article/companyNewsAndPR/idUSBNG15645320070205. Accessed 6 Sep 2007.
42. Varma TR, Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet 1982;20:13-7.
43. Michaelis J, Michaelis H, Gluck E, Keller S. Prospective study of suspected associations between certain drugs administered in early pregnancy and congenital malformations. Teratology 1983;27:57-64.
44. Resseguie LJ, Hick JF, Bruen JA, et al. Congenital malformations among offspring exposed in utero to progestins, Olmstead County, Minnesota 1936-1974. Fertil Steril 1985;43:514-9.
45. Check JH, Rankin A, Teichman M. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril 1986;45:575-7.
46. Katz Z, Lancet M, Skornik J, et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 1985;65:775-80.
47. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980;22:251-70.
48. Raman-Wilms L, Tseng AL, Wighardt S, et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995;85:141-9.
49. Northen A. 4-year follow-up of children exposed to 17 alpha-hydroxyprogesterone caproate (17P) in utero. NICHD MFMU Network [abstract]. Am J Obstet Gynecol 2006;197:S6.
50. Petrini JR, Callaghan WM, Klebanoff M, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267-72.
51. Armstrong JC. 17 Progesterone for preterm birth prevention: a potential 2 billion dollar opportunity [editorial]. Am J Obstet Gynecol 2007;196:194-5.
52. Odibo AO, Stamilio DM, Macones GA, Polsky D. 17 alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis. Obstet Gynecol 2006;108(3 Pt 1):492-9.
53. Ness A, Baxter J, Hyslop T, Berghella V. Progesterone for preventing premature birth: practice patterns of board-certified maternal-fetal medicine specialists in the United States. J Reprod Med 2006;51:411-5.
54. Ness A, Dias T, Damus K, et al. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol 2006;195:1174-9.
55. Kaiser Family Foundation. Number of births financed by Medicaid, 2002. Available at www.statehealthfacts.org/comparemaptable.jsp?ind=222&cat=4. Accessed 21 Sep 2007.
56. U.S. Food and Drug Administration. Cumulative list of all orphan designated products. Available at www.fda.gov/orphan/designat/alldes.rtf. Accessed 6 Sep 2007.